

## PRESS RELEASE



### **Gracell Biotechnologies to Participate in Truist Securities Cell Therapy Symposium**

SAN DIEGO and SUZHOU and SHANGHAI, China, June 20, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today announced that the management team will participate and host investor meetings in the Truist Securities Cell Therapy Symposium: Symposia-cel on June 27, 2023, in New York, NY.

For more information, please visit [ir.gracellbio.com](http://ir.gracellbio.com).

#### **About Gracell**

Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms and SMART CAR™ technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost, and lack of effective CAR-T therapies for solid tumors and autoimmune disease. For more information on Gracell, please visit [www.gracellbio.com](http://www.gracellbio.com). Follow @GracellBio on [LinkedIn](#).

Media contacts Marvin Tang [marvin.tang@gracellbio.com](mailto:marvin.tang@gracellbio.com) Jessica Laub [jessica.laub@westwicke.com](mailto:jessica.laub@westwicke.com) Investor contacts Gracie Tong [gracie.tong@gracellbio.com](mailto:gracie.tong@gracellbio.com) Stephanie Carrington [stephanie.carrington@westwicke.com](mailto:stephanie.carrington@westwicke.com)